Abstract: Disclosed herein are highly sensitive immunoassays that utilize a capture/release mechanism to reduce non-specific binding and achieve detection with attomolar-level sensitivity. Kits that can be used for carrying out these highly sensitive immunoassays are also disclosed herein.

Abstract: An immunochromatography assay kit includes a specimen dropping portion to which a specimen is dropped, a conjugate portion to which a labeled antibody having a property of binding to a detection target in the specimen is immobilized, and a plurality of detection portions to which a capture antibody having a property of binding to the detection target is immobilized. The specimen dropping portion, the conjugate portion, and the plurality of detection portions are formed on a porous member. An outer shape of each detection portion is a dot shape.

Abstract: Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and/or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

Abstract: Methods and compositions for detecting or determining a subject's risk of developing placenta accreta spectrum (PAS) are provided. Biomarkers are described that can be useful in detecting PAS in the second or third trimester of pregnancy.

Abstract: The present invention provides a novel anti-A? antibody capable of detecting an A? related peptide, a method for measuring an A? related peptide in a biological sample by immunochemically using the above-mentioned novel anti-A? antibody, and a kit. A monoclonal antibody that recognizes an A? related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an A? related peptide, comprising the antibody-immobilized carrier.

Abstract: This invention relates to a novel linker compound of formula (i) disclosed herein. The invention also relates to antibody conjugates. The invention relates to methods which utilise the compounds and conjugates disclosed herein.

Abstract: Disclosed is a preparation method for preparing a measurement sample comprising an aggregate of metal nanoparticles having an analyte bound thereto, the preparation method comprising: contacting the analyte with a linker to bind the analyte to the linker; and contacting the linker that has been bound to the analyte with the metal nanoparticles to bind the linker to the metal nanoparticles.

Abstract: The present invention relates to a method for analyzing a biological sample obtained from a subject, comprising analyzing components contained in a biological sample by an assay using a first molecule selected from the group consisting of a molecule binding to a sugar chain bindable with BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.

Abstract: The precision of a lateral flow assay for determining the concentration of an analyte in the plasma fraction of a sample of whole blood can be significantly improved by applying an integrated step for determining the hematocrit of the optionally diluted sample, and taking both hematocrit and dilution factor into account when calculating the concentration of the analyte. This is made possible inter alia by using a predetermined wavelength when taking an image of the sample after application to a substrate in the lateral flow assay device, and wherein said wavelength is selected based on the dilution factor used. This hematocrit measurement is advantageously integrated in lateral flow assay methods and devices for the measurement of an analyte in plasma and contributes significantly to an improved precision of such assays.

Abstract: The invention relates to a process for storing protein-decorated nanoparticles on paper substrates without irreversible binding, and particularly for storing protein-decorated nanoparticles within paper substrates modified with a polymer. The invention also relates to a reservoir containing protein-decorated nanoparticle capable of stablishing biological interactions obtained by the process and its use in biosensors made of paper.

Abstract: The disclosure relates to the technical field of virus detection, in particular, to an IgA antibody and a kit capable of specifically recognizing RBD protein. The antibody can be used as a calibrator of IgA antibody against the RBD protein of SARS-CoV-2. the disclosure further relates to a kit comprising the antibody which enables automated, high-throughput, and rapid detection of IgA antibody against novel coronavirus pneumonia.